Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Summary

Primary Objective: To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative breast cancers (TNBC). Secondary Objectives: 1. To examine the safety and tolerability of dasatinib in patients with operable TNBC 2. To explore potential intracellular mechanisms which impact dasatinib effect on cellular localization of EGFR in operable TNBC. 3. To examine the pathologic complete response (pCR) rates to standard neoadjuvant chemotherapy in nEGFR+ TNBC 4. To examine breast cancer recurrence rates and patterns of metastatic recurrent in nEGFR+ TNBC

Timeline

Start

2017-05-03

Primary completion

2020-07-02

Completion

2022-02-08

Outcome

Outcome not reported

Stopped (Enrollment): “Study terminated early due to COVID-19 related slow enrollment and funding”

Drugs

Indications